| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
320,801 |
421,551 |
1,262,027 |
1,480,093 |
| Total Sell Value |
$21,062,080 |
$26,516,522 |
$74,515,877 |
$82,888,946 |
| Total People Sold |
9 |
9 |
12 |
12 |
| Total Sell Transactions |
28 |
40 |
87 |
90 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Marshbanks Tracy |
Director |
– • – |
2018-05-14 |
4 |
S |
$62.35 |
$343,299 |
I/I |
(5,506) |
382,664 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2018-05-10 |
4 |
S |
$62.03 |
$2,601,871 |
I/I |
(41,914) |
388,170 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2018-05-09 |
4 |
S |
$62.05 |
$1,273,080 |
I/I |
(20,517) |
430,084 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2018-04-18 |
4 |
AS |
$62.09 |
$2,061,388 |
I/I |
(33,200) |
450,601 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2018-04-16 |
4 |
D |
$60.21 |
$6,924 |
D/D |
(115) |
69,333 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2018-04-16 |
4 |
D |
$60.21 |
$14,872 |
D/D |
(247) |
19,754 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-04-16 |
4 |
D |
$60.21 |
$96,998 |
D/D |
(1,611) |
208,631 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2018-04-07 |
4 |
D |
$57.06 |
$8,217 |
D/D |
(144) |
69,448 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-04-07 |
4 |
D |
$57.06 |
$114,919 |
D/D |
(2,014) |
210,242 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2018-04-07 |
4 |
D |
$57.06 |
$22,310 |
D/D |
(391) |
20,001 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2018-04-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,400 |
69,592 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-04-06 |
4 |
A |
$0.00 |
$0 |
D/D |
29,100 |
212,256 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2018-04-06 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
14,118 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2018-04-06 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
20,392 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2018-03-31 |
4 |
D |
$58.22 |
$31,788 |
D/D |
(546) |
12,392 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2018-03-31 |
4 |
D |
$58.22 |
$29,518 |
D/D |
(507) |
6,118 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2018-03-31 |
4 |
D |
$58.22 |
$16,185 |
D/D |
(278) |
65,192 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-03-31 |
4 |
D |
$58.22 |
$148,461 |
D/D |
(2,550) |
183,156 |
|
- |
|
| Holubow Fred |
Director |
– • – |
2018-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
14,811 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2018-03-19 |
4 |
S |
$60.62 |
$322,074 |
I/I |
(5,313) |
289,003 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2018-03-15 |
4 |
S |
$61.50 |
$116,973 |
I/I |
(1,902) |
294,316 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2018-03-14 |
4 |
S |
$63.10 |
$120,647 |
I/I |
(1,912) |
483,801 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2018-03-14 |
4 |
S |
$62.02 |
$119,016 |
I/I |
(1,919) |
296,218 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-03-14 |
4 |
S |
$62.03 |
$620,300 |
D/D |
(10,000) |
185,706 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2018-03-13 |
4 |
S |
$61.81 |
$1,123,023 |
I/I |
(18,117) |
298,137 |
|
- |
|
719 Records found
|
|
Page 13 of 29 |
|
|
0.14 (0.21%) 
